Immuron (IMRN) Cost of Revenue (2016 - 2024)
Immuron's quarterly Cost of Revenue came in at -$874530928.1 billion in Q4 2024, down 112808930498813.45% year-on-year from N/an in Q1 2024, and down 112808930498813.45% quarter-over-quarter from $775232.0 in Q4 2023.
Immuron has reported Cost of Revenue for 9 years, with the latest figure at -$874530928.1 billion in Q4 2024.
- For the quarter ending Q4 2024, Cost of Revenue fell 112808930498813.45% year-over-year to -$874530928.1 billion; the trailing twelve-month figure through Dec 2024 stood at -$874530928.1 billion (down 90126392551963.98% YoY), and the FY2025 full-year result was $312370.5, down 69.59% from the prior year.
- Cost of Revenue for Q4 2024 stood at -$874530928.1 billion, down from $775232.0 in the prior quarter.
- The five-year high for Cost of Revenue was $505.7 million in Q4 2021, with the low at -$874530928.1 billion in Q4 2024.
- Average Cost of Revenue over 5 years is -$109316365.9 billion, with a median of $35474.4 recorded in 2022.
- Year-over-year, Cost of Revenue surged 5542120496576.42% in 2021 and plunged 112808930498813.45% in 2024.
- Tracing IMRN's Cost of Revenue over 5 years: stood at $0.01 in 2020, then surged by 5542120496576.42% to $505.7 million in 2021, then tumbled by 99.97% to $155726.0 in 2022, then surged by 397.82% to $775232.0 in 2023, then sank by 112808930498813.45% to -$874530928.1 billion in 2024.
- The last three Cost of Revenue figures came in at -$874530928.1 billion (Q4 2024), $775232.0 (Q4 2023), and $14310.9 (Q2 2023), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 64.20 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 392.80 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 296.00 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 207.52 Mn |
| 10 | Immuron | 1.27 Bn | 1.27 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -874,530,928.08 Bn |
| Dec 31, 2024 | -874,530,928.08 Bn |
| Dec 31, 2023 | 775,232.00 |
| Dec 31, 2023 | 775,232.00 |
| Jun 30, 2023 | 14,310.93 |
| Jun 30, 2023 | 14,310.93 |
| Dec 31, 2022 | 155,726.00 |
| Dec 31, 2022 | 155,726.00 |
| Jun 30, 2022 | 25,069.39 |
| Jun 30, 2022 | 25,069.39 |
| Dec 31, 2021 | 505.72 Mn |
| Dec 31, 2021 | 505.72 Mn |
| Dec 31, 2020 | 0.01 |
| Dec 31, 2020 | 0.01 |
| Jun 30, 2020 | 45,879.44 |
| Jun 30, 2020 | 45,879.44 |
| Dec 31, 2019 | 4,351.98 |
| Dec 31, 2019 | 4,351.98 |
| Dec 31, 2018 | 231,479.00 |
| Dec 31, 2018 | 231,479.00 |
| Dec 31, 2017 | 152,249.25 |
| Dec 31, 2017 | 152,249.25 |
| Dec 31, 2016 | 168,434.17 |
| Dec 31, 2016 | 168,434.17 |
| Jun 30, 2016 | 225,082.24 |
| Jun 30, 2016 | 225,082.24 |